Ex-Pfizer scientist-led Chinese startup Zai Lab taps banks for $150m IPO

Insilico Medicine

Zai Lab Ltd., a Chinese drug developer working on cancer treatments, has picked banks to arrange a planned U.S. initial public offering that could raise about $150 million, people with knowledge of the matter said.

Continue reading this story with a subscription to DealStreetAsia.